MEDINCELL S.A. |
Market Closed -
Other stock markets
|
After market 03:59:59 pm | |||
| 15.16 EUR | -0.39% |
|
15.18 | +0.13% |
| May. 15 | Medincell: share price falls after disappointing clinical study | CF |
| May. 15 | Transcript : MedinCell S.A. - Special Call |
| Sales 2024 * | 13.96M 15.18M | Sales 2025 * | 41.8M 45.46M | Capitalization | 442M 481M |
|---|---|---|---|---|---|
| Net income 2024 * | -23M -25.01M | Net income 2025 * | 1M 1.09M | EV / Sales 2024 * | 35.2 x |
| Net Debt 2024 * | 48.73M 53M | Net Debt 2025 * | 58.83M 63.98M | EV / Sales 2025 * | 12 x |
| P/E ratio 2024 * |
-16.7
x | P/E ratio 2025 * |
-285
x | Employees | 138 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 50.03% |
More Fundamentals
* Assessed data
More news
Latest transcript on MedinCell S.A.
More press releases
More news
| 1 day | -0.53% | ||
| 1 week | +7.38% | ||
| Current month | +5.43% | ||
| 1 month | +9.71% | ||
| 3 months | +62.62% | ||
| 6 months | +144.19% | ||
| Current year | +110.28% |
1 week
14.02
15.56
1 month
12.7417.50
Current year
6.9117.50
1 year
5.2517.50
3 years
4.7317.50
5 years
4.3520.00
10 years
4.3520.00
| Managers | Title | Age | Since |
|---|---|---|---|
Christophe Douat
CEO | Chief Executive Officer | 60 | 03-01-08 |
Stéphane Postic
DFI | Director of Finance/CFO | 50 | 23-08-31 |
| Chief Tech/Sci/R&D Officer | - | 14-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sabri Markabi
BRD | Director/Board Member | - | 17-07-04 |
Tone Kvåle
BRD | Director/Board Member | 55 | 22-06-12 |
Virginie Lleu
BRD | Director/Board Member | - | 16-05-24 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-28 | 15.16 | -0.39% | 45 067 |
| 24-05-27 | 15.22 | +1.87% | 84,825 |
| 24-05-24 | 14.94 | +2.47% | 51,555 |
| 24-05-23 | 14.58 | +1.96% | 36,139 |
| 24-05-22 | 14.3 | +1.42% | 45,615 |
Real-time Euronext Paris, May 28, 2024 at 08:48 am EDT
More quotes
MedinCell S.A. is a pharmaceutical company that develops a portfolio of long-acting injectable products in various therapeutic areas, combining its proprietary BEPO® technology with active ingredients already known and marketed. The BEPO® technology allows the regular delivery of a drug at optimal therapeutic dose for several days, weeks or months from the subcutaneous or local injection of a simple deposit of a few millimeters, fully bioresorbable.
As of March 31, 2023, the company had a portfolio of 2 products in phase 3 clinical development and 6 products in preclinical development. Its most advanced product, mdc-IRM/UZEDYTM for the treatment of schizophrenia, has received marketing authorization in the United States.
Sector
Pharmaceuticals
Calendar
2024-06-06
- Jefferies Global Healthcare Conference
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
15.22
EUR
Average target price
19.24
EUR
Spread / Average Target
+26.41%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +110.28% | 480M | |
| +38.51% | 727B | |
| -6.23% | 354B | |
| +18.78% | 328B | |
| +1.35% | 277B | |
| +14.57% | 243B | |
| +7.58% | 205B | |
| -6.01% | 203B | |
| +6.19% | 164B | |
| +0.31% | 164B |
- Stock Market
- Equities
- MEDCL Stock
